JP2021505137A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505137A5
JP2021505137A5 JP2020530356A JP2020530356A JP2021505137A5 JP 2021505137 A5 JP2021505137 A5 JP 2021505137A5 JP 2020530356 A JP2020530356 A JP 2020530356A JP 2020530356 A JP2020530356 A JP 2020530356A JP 2021505137 A5 JP2021505137 A5 JP 2021505137A5
Authority
JP
Japan
Prior art keywords
sequence number
amino acid
chain variable
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020530356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505137A (ja
JP7089806B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2018/015445 external-priority patent/WO2019112347A2/ko
Publication of JP2021505137A publication Critical patent/JP2021505137A/ja
Publication of JP2021505137A5 publication Critical patent/JP2021505137A5/ja
Application granted granted Critical
Publication of JP7089806B2 publication Critical patent/JP7089806B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020530356A 2017-12-06 2018-12-06 悪性b細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 Active JP7089806B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170166969 2017-12-06
KR10-2017-0166969 2017-12-06
PCT/KR2018/015445 WO2019112347A2 (ko) 2017-12-06 2018-12-06 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도

Publications (3)

Publication Number Publication Date
JP2021505137A JP2021505137A (ja) 2021-02-18
JP2021505137A5 true JP2021505137A5 (https=) 2021-12-02
JP7089806B2 JP7089806B2 (ja) 2022-06-23

Family

ID=66749962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530356A Active JP7089806B2 (ja) 2017-12-06 2018-12-06 悪性b細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途

Country Status (8)

Country Link
US (2) US11534462B2 (https=)
EP (1) EP3722313A4 (https=)
JP (1) JP7089806B2 (https=)
KR (1) KR102136063B1 (https=)
CN (1) CN111465616B (https=)
AU (1) AU2018379502B2 (https=)
CA (1) CA3083936C (https=)
WO (1) WO2019112347A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079111A1 (en) * 2018-08-04 2021-03-18 AbCyte Therapeutics Inc. Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112759651B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种包含嵌合抗原受体修饰的t细胞及其应用
CN111909277A (zh) * 2020-08-13 2020-11-10 上海市第一人民医院 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途
KR102393776B1 (ko) * 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
WO2022234158A1 (es) * 2021-05-06 2022-11-10 Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) Terapia de células t con receptor de antígeno quimérico específico de cd19
WO2023201339A1 (en) 2022-04-15 2023-10-19 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
US20240261405A1 (en) 2022-06-08 2024-08-08 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
EP4653467A1 (en) * 2023-01-19 2025-11-26 Wuhan Zhaozhi Biotechnology Co., Ltd. Car molecule, cell or exosome containing same, and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US7169894B2 (en) * 2001-11-14 2007-01-30 Mirari Biosciences, Inc. Methods and compositions for reverse translation
US20060280738A1 (en) 2005-06-08 2006-12-14 Tedder Thomas F Anti-CD19 antibody therapy for transplantation
KR101335798B1 (ko) 2005-02-15 2013-12-02 듀크 유니버시티 항-cd19 항체 및 종양학에서 이의 용도
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2398829A2 (en) * 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
MX2011009312A (es) 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
WO2010126590A1 (en) * 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
PL3546572T3 (pl) 2013-05-13 2024-07-22 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
GB2527285B (en) 2014-06-11 2021-05-26 Advanced Risc Mach Ltd Resource access control using a validation token
TWI805109B (zh) * 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
CN109824778B (zh) 2015-09-18 2022-07-19 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
IL299203A (en) 2015-10-13 2023-02-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody factors specific for human differentiation group 19 and their uses

Similar Documents

Publication Publication Date Title
JP2021505137A5 (https=)
JP7404335B2 (ja) Bcma特異性を有するキメラ抗原受容体およびその使用
CN109485734B (zh) 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
JP7721500B2 (ja) Mage-a4特異性を有するキメラ抗原受容体およびそれらの使用
CA3032581A1 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
KR20180054590A (ko) 항글리피칸-3 항체 및 이의 응용
JP2018526028A5 (https=)
US20240123068A1 (en) Cd19 binders, car-t constructs comprising the same, and methods of using the same
EP3526257A2 (en) Modular tetravalent bispecific antibody platform
CN111848809A (zh) 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
CN114391021A (zh) TGF-β受体和使用方法
TW202246504A (zh) 靶向嵌合抗原受體之ror1
KR20230022422A (ko) 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
KR20240013173A (ko) Nkg2d-기초 키메라 항원 수용체
US20240226154A9 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
JP7080514B2 (ja) 悪性b細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
TW202309294A (zh) 病毒載體生產系統
JP2021529539A5 (https=)
JPWO2021016585A5 (https=)
KR20240052776A (ko) Mog-결합 단백질 및 이의 용도
JPWO2022235662A5 (https=)
AU2023230479A1 (en) Antibody or antigen-binding fragment thereof that targets cotinine, chimeric antigen receptor comprising same, and uses thereof
TW202435913A (zh) 針對血癌之抗體
AU2023259611A1 (en) Modified cytotoxic t cells and methods of use thereof
HK40072388A (zh) TGF-β受体和使用方法